Evaluation of PCR-Reverse Dot Blot Human Papillomavirus Genotyping Test in Predicting Residual/Recurrent CIN 2+ in Posttreatment Patients in China.
cell biology
genotype
histology
papillomavirus
postoperative
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
11
2019
accepted:
13
03
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
21
4
2020
Statut:
epublish
Résumé
To assess the clinical value of the PCR-reverse dot blot human papillomavirus genotyping test during follow-up of patients with CIN grade 2 or worse (CIN 2+). Four hundred patients with CIN 2+ receiving treatment from January 2008 to January 2017 were included in our study. Postoperative follow-up procedures comprised HPV examination and cervical cytology every 3-6 months for the first 2 years and then followed up every 6-12 months. A pathology examination was performed when there was a positive funding for HPV 16/18 or an abnormal ThinPrep cytology test (TCT) with or without positive for HR-HPV according to the American Society for Coloscopy and Cervical Pathology (ASCCP) guidelines. The median follow-up period was 27.10±12.47 months (ranging from 3 to 50 months). During follow-up, 12.00% (48/400) of the women developed residual/recurrent disease. The highest risk in CIN 2+ and CIN 3+ residual/recurrence was HPV-16/-18 (hazard ratio (HR)=12.898, 95% CI= 6.849-24.289; HR= 20.726, 95% CI= 9.64-44.562, respectively). Among the different follow-up methods, type-specific (TP) HR-HPV persistent infection showed the highest cumulative incidence risk (CIR) (84.62%, 95% CI=73.29-95.94) and HR (5.38, 95% CI= 2.596-11.149) during the 4-year follow-up period. At the CIN 2+ and CIN 3+ endpoints, TP-HPV testing had relatively high sensitivity (84.62%, 95% CI=73.29-95.94 and 89.28%, 95% CI= 77.83-100.00, respectively) and specificity (78.07%, 95% CI= 72.70-83.44 and 75.73%, 95% CI= 70.30-81.17, respectively). However, at the CIN 2+/CIN 3+ endpoint, TCT follow-up had a sensitivity of 60.42%/62.16% (95% CI=46.58-72.25/46.54-77.79) and specificity of 90.18%/88.72% (95% CI=86.95-93.41/85.35-92.10). TP HR-HPV follow-up can provide a reliable and sensitive clinical reference for CIN 2+ postoperative patients.
Identifiants
pubmed: 32308477
doi: 10.2147/CMAR.S237490
pii: 237490
pmc: PMC7132552
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2369-2379Informations de copyright
© 2020 Zhang et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Am J Obstet Gynecol. 2010 Jul;203(1):72.e1-6
pubmed: 20417477
Am J Obstet Gynecol. 2009 Jul;201(1):17.e1-8
pubmed: 19344881
Updates Surg. 2017 Dec;69(4):441-449
pubmed: 28918603
J Clin Diagn Res. 2014 Sep;8(9):OC26-30
pubmed: 25386491
Obstet Gynecol. 2013 Dec;122(6):1338-67
pubmed: 24264713
Arch Gynecol Obstet. 2019 Feb;299(2):299-315
pubmed: 30542793
Lancet Oncol. 2018 Dec;19(12):1569-1578
pubmed: 30392810
J Infect Dis. 2015 Jan 1;211(1):100-8
pubmed: 25028692
Gynecol Obstet Invest. 2015;80(3):153-63
pubmed: 25832290
Eur J Obstet Gynecol Reprod Biol. 2018 Sep;228:174-179
pubmed: 29960201
Menopause. 2016 Jan;23(1):81-6
pubmed: 26057824
Int J Cancer. 2013 Sep 15;133(6):1271-85
pubmed: 22961444
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):908-14
pubmed: 16702369
Eur J Surg Oncol. 2011 Jun;37(6):537-42
pubmed: 21511424
Updates Surg. 2017 Sep;69(3):383-388
pubmed: 28466456
Am J Epidemiol. 2003 Sep 1;158(5):486-94
pubmed: 12936904
Int J Cancer. 2011 Aug 15;129(4):903-9
pubmed: 21064091
BMJ. 2009 Apr 24;338:b1354
pubmed: 19395420
BMJ. 2018 Feb 27;360:k499
pubmed: 29487049
Gynecol Oncol. 2012 Nov;127(2):367-74
pubmed: 22800653
BMJ. 2015 Jun 30;350:h2372
pubmed: 26126623
Eur J Cancer. 2010 Jun;46(9):1502-13
pubmed: 20227872
J Low Genit Tract Dis. 2013 Jan;17(1):38-47
pubmed: 22885643
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Int J Cancer. 1995 Dec 11;63(6):804-9
pubmed: 8847138
J Gynecol Oncol. 2017 Sep;28(5):e50
pubmed: 28657218
Eur J Gynaecol Oncol. 2016;37(5):685-688
pubmed: 29787011
Vaccine. 2012 Nov 20;30 Suppl 5:F88-99
pubmed: 23199969
J Med Virol. 2014 Apr;86(4):634-41
pubmed: 24123176
Lancet Oncol. 2011 May;12(5):441-50
pubmed: 21530398